Human epidermal growth factor receptor 2 (HER2) is a proto-oncogene [2] and is overexpressed in nearly 20% of breast cancer patients, which leads to high recurrence rates and poor prognosis of HER2-positive breast cancer [3]. Here, ERBB2 is linked to breast carcinoma.